Skip to main content
Premium Trial:

Request an Annual Quote

Illumina's Stock Jumps 16 Percent on Affy Settlement

NEW YORK (GenomeWeb News) - Illumina’s stock rose nearly 16 percent, to $70.02, in afternoon trading after this morning’s news that the company will settle its longstanding patent-infringement litigation with Affymetrix without admitting liability and without paying royalties.
 
Under the terms of the settlement, Illumina will pay Affy $90 million and the companies agreed to a covenant not to sue each other in the future.
 
Affymetrix’s stock, meanwhile, fell nearly 5 percent, to $22.62, from yesterday’s closing price of $23.76.
The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.